Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

John Rubino,Diane E MacDougall,Lulu Ren Sterling, Stephanie E Kelly,James M McKenney,Narendra D Lalwani

Journal of Clinical Lipidology（2021）

引用 27|浏览18

暂无评分

摘要

•Bempedoic acid added to PCSK9 inhibitor therapy lowered LDL-C by 30.3% vs placebo.•Bempedoic acid significantly lowered Apo B, non-HDL-C, total cholesterol, and hsCRP.•The safety profile of bempedoic acid in combination with a PCSK9i was generally comparable to placebo.

查看译文

关键词

ATP citrate lyase inhibitor,Hypercholesterolemia,Lipid-lowering,C-reactive protein,PCSK9 inhibition

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要